GSK’s RSV vaccine ‘Arexvy’ receives positive European Medicines Agency’s CHMP opinion for adults aged 50-59
Decision on EU marketing authorisation for this population expected by September 2024
Decision on EU marketing authorisation for this population expected by September 2024
Access to breast milk for sick newborns admitted in intensive care units plays a lifesaving role
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
Theophylline is used to treat asthma and chronic obstructive pulmonary disease
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Vision loss due to Glaucoma can be prevented if it is detected and treated early
Subscribe To Our Newsletter & Stay Updated